Abstract |
Doxorubicin (ADM) and epirubicin (epi-ADM) were tested at a dose of 150mg given intraarterially to 31 patients (ADM 14, epi-ADM 17) with advanced breast cancer. The clinical response rate was 78.6% in ADM (1 CR and 10 PR) and 76.5% in epi-ADM (1 CR and 12 PR). The histological response rate of 57.1% was also obtained in ADM and 56.3% in epi-ADM. No significant differences were evident between the two drugs. As for side effects, hair loss and gastrointestinal disorders were frequently documented low grade and less following administration of epi-ADM as compared to ADM. A more favorable prognosis seems possible with epi-ADM compared with ADM. Intra-arterial infusion chemotherapy with epi-ADM appears to be effective for the treatment of advanced breast cancer and is less toxic that ADM.
|
Authors | E Yayoi, J Furukawa, Y Takatsuka, T Kobayashi, T Aikawa, Y Maeura, M Kaji, Y Kotsuma |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 19
Issue 10 Suppl
Pg. 1621-4
(Aug 1992)
ISSN: 0385-0684 [Print] Japan |
PMID | 1530320
(Publication Type: Comparative Study, English Abstract, Journal Article)
|
Chemical References |
|
Topics |
- Alopecia
(chemically induced)
- Breast Neoplasms
(drug therapy, mortality)
- Doxorubicin
(administration & dosage, adverse effects)
- Epirubicin
(administration & dosage, adverse effects)
- Female
- Humans
- Infusions, Intra-Arterial
- Leukopenia
(chemically induced)
- Subclavian Artery
- Survival Rate
|